The first microtechnological 3D trap capable of accelerating cancer characterization

Smartcatch is lifting the current locks on CTC liquid biopsy by developing a range of compact, portable, easy-to-use products that can equip consulting rooms and adapt to use in clinical routines, in order to democratize liquid biopsy and make it truly the essential medical procedure for the diagnosis, follow-up and personalization of care in medical oncology.

the biology of ctc

Circulating Tumor Cells (CTC) can be found in the blood of every cancer patient, and are responsible for metastasis

Circulating tumour cells (CTCs) are cancer cells that have escaped from a tumour and migrated through different biofluids in the human body. These tumour cells travel through the bloodstream until they find a suitable niche to proliferate and develop a secondary metastasis or tumour, the leading cause of death by cancer. They therefore carry key information about the presence, nature and aggressiveness of solid tumours.
They convey crucial information in terms of number, genetics, molecular pathways, mechanisms of immune evasion – their detection, counting and analysis could help the oncologist to refine his diagnosis and prognosis, adapt the therapy at the individual level and monitor more closely the evolution of the disease over time and the effectiveness of the treatments provided.

Microtechnologies as a tool for precision medicine

Microtechnologies encompasses the scope of new materials, structures with ultimate resolution, and sensors with ultimate sensitivity, where the micron-scale achieved by these cutting-edge technologies meets the scale of CTC.

CTC capture

How does it work?

Circulating Tumor Cells are relatively larger and less deformable than other blood cellular components. SmartCatch exploits the physical characteristics of CTCs for their capture on the basis of size and rigidity.

Implemented in physiological conditions (low-pressure regimes, unprocessed blood), SmartCatch’s goal is to provide the specific isolation of unaltered cells not depending on the evasive expression of membrane markers, and representative of CTC diversity.


The core of the innovation consists in a microengineered capture device, developed with cutting-edge technologies and advanced computational simulations, enabling a one-step physical and selective isolation of CTC in physiological conditions while preserving their native state.

The company’s objective is to be able to access the clinics and offer products that are compatible with clinical routine to improve patient care.

Looking for a mild technique for CTC capture?

Reach out to us !
We develop solutions that meet your needs.

Contact us